#United States #Nashville #oncology #Cancer Care #Thyme Care

Thyme Care's Significant Encounter with Series E Financing

Thyme Care, a prominent player in the oncology sector, has recently raised over $125 million in a Series E funding round, bolstered by investors including Morgan Health, CVS Health Ventures, and Humana. This substantial capital influx not only implies a strong investor confidence in the company's service model but also sets the stage for the establishment of a new parent entity, Thyme Companies, which aims to enhance its impact across various stages of the cancer care journey.

A Sign of Growth and Trust in the Oncology Ecosystem

The financing round gathered support from significant stakeholders throughout the cancer care ecosystem, marking Thyme Care's emergence as a leader in this challenging field. With this investment, Thyme Care's valuation now exceeds $2 billion. The backing from major national payers, community oncology groups, and health systems accentuates a shared vision: improving the quality and accessibility of cancer treatment.

Thyme Care currently provides services to more than 10.5 million individuals nationwide and manages an impressive oncology spend estimated at over $7 billion. Their innovative care model has demonstrated reductions in overall care costs by 5 to 10 percent, showcasing their efforts to not only enhance patient care but also create financial value for healthcare plans and providers. Their dedication to financial accountability and operational discipline has rendered them profitable while producing meaningful positive cash flow.

Innovating Cancer Care with Thyme Companies

In conjunction with the Series E funding, Thyme Care is launching Thyme Companies to build a portfolio of independent ventures aimed at addressing persistent challenges within oncology care. Recognizing that a holistic approach is crucial to improving patient outcomes, the newly formed company will focus on accelerating the adoption of cost-effective biosimilars and enhancing the accrual of clinical trials, where slow enrollment remains an obstacle to patient access and drug development. The executives associated with Thyme Companies envision launching the first of these new businesses later this year.

Thriving under the leadership of its co-founders, Robin Shah, who will take on the role of executive chairman, and Bobby Green, M.D., who continues as their co-founder and takes on the mantle of President and Chief Medical Officer, Thyme Care will remain at the core of the new company structure. Under the stewardship of current CEO Brad Diephuis, the commitment to a patient-first approach remains unchanged.

A Vision for the Future

With the initiation of Thyme Companies, the opportunity to address the complexities of cancer care is broader than ever. Robin Shah remarked, "When we founded Thyme Care, our goal extended beyond one component of cancer treatment. We aimed for a revolutionary oncology care framework." The insights gathered from experiences over the years have shaped Thyme's strategic actions going forward, reinforcing their mission to realize a more effective oncology model.

As the new entity embarks on this transformative journey, it stands as a testament to the changing landscape of cancer care, steered by a commitment to innovation and patient well-being. Thyme Companies symbolizes the next chapter in a story dedicated to reshaping how cancer care can be delivered, accessed, and financed on an unprecedented scale.

About Thyme Care and Thyme Companies

Thyme Care is dedicated to coordinating a seamless cancer care approach by aligning patients, healthcare providers, and health plans around a unified model that drives superior outcomes while minimizing costs. Their integrated systems empower care teams with technology to support patients over the duration of their treatments, closing gaps between visits and aligning clinic decisions with fiscal accountability.

For more detailed information, one can explore Thyme Care and Thyme Companies.